We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Investors Watch Generational Marriage Delays as Housing Demand Softens

Podcast Spotlights Generational Delay in Marriage

Vinay Lochav | 17 August 2026

Evolution Metals & Technologies Q2 2026 10-Q Filing

Evolution Metals & Technologies Corp. filed its quarterly report on Form 10-Q with the SEC for the period ended June 30, 2026, disclosing condensed consolidated financial statements and management discussion as of August 17, 2026.

Vinay Lochav | 17 August 2026

argenx (NASDAQ: ARGX) Phase 3 ALKIVIA Trial Achieves Primary Endpoint in Autoimmune Myositis

argenx SE (NASDAQ: ARGX) announced that its Phase 3 ALKIVIA trial for Vyvgart Hytrulo in autoimmune myositis achieved its primary objective, with the combined IMNM/DM group demonstrating a statistically significant 15.4-point TIS advantage over placebo at 52 weeks.

Nitish Kishor | 17 August 2026

OmniAb (NASDAQ: OABI) Shares Rise 18% on Raised Cash Outlook and Eli Lilly Deal

OmniAb, Inc. (NASDAQ: OABI) shares rose nearly 18% premarket after the company raised its 2026 year-end cash outlook to $49 million to $53 million, up from $37 million to $41 million, following recent technology licensing and business development activity.

Nitish Kishor | 17 August 2026

Citius Pharmaceuticals (NASDAQ: CTXR) Q3 Results Miss Estimates as LYMPHIR Rollout Begins

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) posted third-quarter results that trailed expectations, with a GAAP net loss of $0.34 per share falling $0.09 short of consensus estimates.

Nitish Kishor | 17 August 2026

Adial Pharmaceuticals (NASDAQ: ADIL) Completes Azora Therapeutics Acquisition, Shifts Focus to AT177

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) completed itsAcquisitionof Azora Therapeutics, shifting focus to AT177, an oral colon-targeted AhR agonist for ulcerative colitis, while closing the first $32 million tranche of up to $64 million in financing.

Nitish Kishor | 17 August 2026

Quantum BioPharma (NASDAQ: QNTM) Gets Regulatory Green Light for Phase 2 Lucid-MS Study

Quantum BioPharma Ltd. (NASDAQ: QNTM) second-quarter results revealed a fortifiedLiquidityposition, with cash and digital holdings totaling approximately $9.5 million, extending its operational horizon into late 2027.

Nitish Kishor | 17 August 2026

EyePoint Pharmaceuticals (NASDAQ: EYPT) Phase 3 LUGANO Trial Misses Primary Endpoint in Wet AMD

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) reported that its Phase 3 LUGANO trial for DURAVYU in wet age-related macular degeneration missed the primary best-corrected visual acuity endpoint in the full dataset.

Nitish Kishor | 17 August 2026

Icon Energy (NASDAQ:ICON) Stock: Q1 Profit Overshadowed by 86% Insider Control

Icon Energy Corp. (NASDAQ:ICON), an Athens-based owner of three dry bulk carriers, did something unusual for a shipping micro-cap in early 2026: it started earning money. It swung to a first-quarter profit on a fleet running near full utilisation, and locked in charter cover …

Vinay Lochav | 17 August 2026

Flux Power (NASDAQ:FLUX) Launches AI-Powered SkyEMS 3.0 as a $40 Million Equity Line and a Lender Covenant Default Redefine the Story

Flux Power Holdings, Inc. (NASDAQ:FLUX) buildsLithium-Ion Batterypacks that replace lead-acid batteries and propane in forklifts, airport ground support vehicles and other industrial equipment. It tells investors two stories at once: a product line still winning attention, and aBalance Sheetcarrying a going-concern warning.

Vinay Lochav | 17 August 2026
Support

Hi! How can we help you today?

Loading…